CNS Pharmaceuticals (CNSP) investor relations material

Executive summary

• Focused on developing anti-cancer drug candidates for CNS tumors, with lead assets TPI 287 and Berubicin targeting Glioblastoma and other malignancies.

• TPI 287 and Berubicin have Orphan Drug Designation from the FDA, providing potential market exclusivity.

• March 2025 topline data for Berubicin showed no statistically significant difference in overall survival versus standard of care, but comparable outcomes and ongoing evaluation of next steps.

• Exclusive license agreement for TPI 287 signed with Cortice Biosciences in July 2024, with milestone and royalty obligations.

Financial highlights

• Net loss for Q3 2025 was $3.2 million, down from $5.6 million in Q3 2024; nine-month net loss was $9.9 million, down from $11.7 million year-over-year.

• General and administrative expenses for Q3 2025 were $1.1 million, down from $1.4 million in Q3 2024; R&D expenses were $2.2 million, down from $4.2 million.

• Cash and cash equivalents as of September 30, 2025, were $9.9 million, up from $6.5 million at year-end 2024.

• Working capital at quarter-end was $9.4 million.

Outlook and guidance

• Estimated working capital sufficient to fund operations into the second half of 2026, assuming core expense run rate of $5.5 million/year.

• TPI 287 trial expected to initiate in Q2 2026, with estimated trial cost of $12–15 million, requiring significant additional financing.

• No commitments for additional financing; may need to raise funds through equity or debt.